Exploring how inflammation and genetics predict atrial fibrillation recurrence
Impact of Inflammatory Indexes and Gene Scores in Prediction of Atrial Fibrillation - IERV Trial
Vrinnevi Hospital · NCT06399666
This study is testing whether inflammation and genetic factors can help predict if atrial fibrillation will come back after treatment in adults with the condition.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 182 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Vrinnevi Hospital (other) |
| Locations | 2 sites (Jönköping, Småland and 1 other locations) |
| Trial ID | NCT06399666 on ClinicalTrials.gov |
What this trial studies
This observational study aims to investigate the role of inflammatory indexes and genetic scores in predicting the recurrence of atrial fibrillation (AF) after electrical cardioversion. It will include 182 patients with persistent AF who are over 18 years old and will collect blood samples before the procedure and at various follow-up intervals. The study will evaluate AF recurrence through 12-lead ECGs and analyze the data using logistic regression methods. The goal is to identify more effective prediction models for AF recurrence based on these biomarkers.
Who should consider this trial
Good fit: Ideal candidates for this study are adults over 18 years old with persistent atrial fibrillation scheduled for electrical cardioversion.
Not a fit: Patients with autoimmune diseases, inflammatory conditions, liver dysfunction, ongoing infections, thyroid disorders, or other conditions affecting inflammatory activity may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to improved prediction models for atrial fibrillation recurrence, potentially enhancing patient management and outcomes.
How similar studies have performed: Previous studies have focused on specific inflammatory markers, but this approach of integrating multiple inflammatory indexes and genetic scores is relatively novel.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Persistent atrial fibrillation (ICD-10 I48.1) * Age over 18 years Exclusion Criteria: * Autoimmune disease * Inflammatory diseases * Acute or chronic liver dysfunction * Ongoing infectious diseases * Thyroid disorders * Any other conditions known to impact inflammatory activity (including medication use and hematological diseases)
Where this trial is running
Jönköping, Småland and 1 other locations
- Medical department — Jönköping, Småland, Sweden (RECRUITING)
- Cardiology Clinic — Norrköping, Östergötland County, Sweden (RECRUITING)
Study contacts
- Study coordinator: Jakob Hytting, MD
- Email: jakob.hytting@liu.se
- Phone: +46 + 707679724
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions: Atrial Fibrillation, Inflammation, Genetic Predisposition to Disease